SEZ6L2, His, Human
SEZ6L2, His, Human

The purity of SEZ6L2, His, Human is greater than 95% as determined by SEC-HPLC.

SEZ6L2, His, Human

SEZ6L2, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEZ6L2, His, Human

Seizure-related 6 homolog (mouse)-like 2 (SEZ6L2) was shown to be involved in transcription of a type 1 transmembrane protein for regulating cell fate. SEZ6L2 was significantly up-regulated in tumour tissues of patients with CRC compared with adjacent normal tissues. Up-regulation of SEZ6L2 was correlated with a poor prognosis in patients with CRC. Furthermore, SEZ6L2 expression was inversely correlated with the expression of cytochrome C in malignant tissues in patients with CRC.
Z05811
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
SEZ6L2 (Leu28-Asn844)_x000D_
Accession # Q6UXD5-1		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 88.5 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 120-140 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • SEZ6L2, His, Human
    • SEZ6L2, His, Human

    The purity of SEZ6L2, His, Human is greater than 95% as determined by SEC-HPLC.

  • SEZ6L2, His, Human
    • SEZ6L2, His, Human

    SEZ6L2, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Seizure-related 6 homolog (mouse)-like 2 (SEZ6L2) was shown to be involved in transcription of a type 1 transmembrane protein for regulating cell fate. SEZ6L2 was significantly up-regulated in tumour tissues of patients with CRC compared with adjacent normal tissues. Up-regulation of SEZ6L2 was correlated with a poor prognosis in patients with CRC. Furthermore, SEZ6L2 expression was inversely correlated with the expression of cytochrome C in malignant tissues in patients with CRC.
Synonyms BSRP-A; PSK-1; SEZ6L2; UNQ1903/PRO4349

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.